T-cell Acute Lymphoblastic Leukemia: towards a personalized medicine
Sala Juntas, Edificio Politécnico
Monday February 04, 2019

Conferencia Eulalia Genesca

Josep Carreras Leukaemia Research Institute (IJC)

4 de febrero de 2019

12:45h. Sala Juntas E.T.S.I.Industriales

Evolution of the diagnosis and treatment of the T-cell Acute Lymphoblastic Leukemia (T-ALL): moving toward a personalized medicine

Acute lymphoblastic leukemia (ALL) is the result of an oncogenic process leading to the blockage of maturation and malignant transformation of hematopoietic lymphoid precursors. T-ALL is the less common subtype and the most complex and heterogeneous at the genetic level. Genetics plays a key role in the development of T-ALL and has a prognostic value. However, so far, only cytogenetic data have been taken into account at the diagnosis. Being genetically different, adult patients with T-ALL are treated with the same protocols as those with LAL-B and the vast majority relapse. In addition, it is the subtype with fewer new therapeutic alternatives available. Nowadays large-scale genomic techniques allow to obtain a large amount of genetic data that can help to improve the stratification of these patients and also allow to design new and more specific therapeutic alternatives to apply to these new oncogenetic subgroups